Oesophagostomum medical therapy

Revision as of 14:42, 5 December 2012 by Hardik Patel (talk | contribs)
Jump to navigation Jump to search

Oesophagostomum Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oesophagostomum from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oesophagostomum medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oesophagostomum medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onOesophagostomum medical therapy

CDC on Oesophagostomum medical therapy

medical therapy in the news

on Oesophagostomum medical therapy

Directions to Hospitals Treating Oesophagostomum

Risk calculators and risk factors for Oesophagostomum medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

The typical adult therapy for oesophagostomiasis is a single 400 mg dose of albendazole (200 mg for children) or pyrantel pamoate.[1] Albendazole works by binding to the free beta tubulin, which inhibits tubulin polymerization. This results in the inhibition of glucose uptake by the Oesophagostomum. Albendazole and pyrantel pamoate at these doses have cure rates of 85% and 59-82%, respectively. Excision of Oesophagostomum larvae from nodules has been shown to have a curative effect on the patient but is invasive and more resource intensive than chemotherapy.

For oesophagostomiasis with complications, the type of treatment varies depending on the severity of the disease. Usually 200–400 mg of albendazole will be given immediately and continued for up to 5 days in conjunction with 250 mg dosages of amoxicillin.[2]

References

  1. “GIDEON Infectious Diseases - Diseases.” GIDEON Infectious Disease Database. 5 Feb 2009. <http://web.gideononline.com/web/epidemiology/index.php?gdn_form=ZGlzZWFzZT0xMTY1MA==>.
  2. Ziem, J.B. “Controlling human oesophagostomiasis in northern Ghana.” (Doctoral thesis) Leiden University. 2006. <https://openaccess.leidenuniv.nl/dspace/handle/1887/4917?mode=more>.

Template:WH Template:WS